Cybersecurity and Radiation Oncology
Radiation oncology centers have been victims of cyberattacks in recent years. Given the connectedness of radiation oncology IT, all radiation oncology centers are vulnerable to cyberattacks that can impact every stage of radiation treatment from patient check in, to treatment planning and delivery, to recording and verification of treatment. This panel session - consisting of experts from radiation oncology and information technology – will educate the radiation oncology community on recent cyberattacks at major institutions and meaningful actionable steps to minimize cybersecurity risks
This activity is available from March 17, 2023, through 11:59 p.m. Eastern time on March 16, 2024.
This activity was originally recorded at ASTRO’s Annual Meeting on October 26, 2022.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists, radiation dosimetrists, medical oncologists, surgeons, nurses, diagnostic radiologists, pathologists, radiation therapists and radiation biologists.
Upon completion of this activity, participants:
- Understand and establish protocols in the event of a cyberattack.
- Learn from recent cyberattacks on radiation oncology facilities and about potential vulnerabilities.
- Know how to develop and maintain a high level of cybersecurity at a radiation oncology facility.
C Jillian Tsai, MD, PhD, is employed by Memorial Sloan Kettering Cancer Center and receives compensation from Nanobiotix and Varian.
Adam Dicker, MD, PhD, FASTRO, is employed by Sidney Kimmel Medical College of Thomas Jefferson University and receives compensation from CVS, European Commission, Hengrui, Janssen, Oncohost, and Oranomed.
Matthew Zawalich, MS, is employed by Yale New Haven Hospital.
Nataniel H. Lester-Coll, MD, is employed by University of Vermont Medical Center.
James B. Yu, MS, MHS, is employed by Columbia University Irving Medical Center and the Yale School of Medicine. He receives compensation from Augmenix/Boston Scientific, Galera Pharmaceuticals, Pfizer and RefleXion.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.